Literature DB >> 12797908

Immune system alterations in lung cancer patients.

G Mazzoccoli1, M Grilli, S Carughi, F Puzzolante, A De Cata, M La Viola, A Giuliani, N Urbano, R Tarquini, F Perfetto.   

Abstract

The immune system plays an important role in the defense against neoplastic disease and immune responses show temporal changes related to circadian variations of antibodies, total lymphocytes in the peripheral blood and cell mediated immune responses. In this study we evaluate. lymphocyte subpopulations and interleukin-2 (IL-2) serum levels in peripheral blood samples collected at four-hour intervals for 24-hours starting at 06.00 h from ten healthy subjects aged 65-79 years (mean age +/- s.e. 67.28 +/- 3.11) and from ten subjects suffering from untreated non small cell lung cancer aged 65-78 years (mean age +/- s.e. 68.57 +/- 1.81). Areas under the curve, mean diurnal levels (mean of 06.00-10.00-14.00 h) and mean nocturnal levels (mean of 18.00-22.00-02.00 h) were calculated, and the presence of circadian rhythmicity was evaluate. When we compared AUC values there was a decrease in CD8bright (T suppressor subset) and an increase in CD16 (natural killer cells) and of IL-2 serum levels in cancer patients. When we compared mean diurnal levels, CD8 (T suppressor/cytotoxic subset) and CD8bright levels were lower, and CD16 levels were higher in cancer patients. When we compared mean nocturnal levels, CD16 and CD25 (T and B activated lymphocytes with expression of the a chain of IL-2 receptor) levels were higher, while CD8, CD8bright, CD20 (total B-cells), TcRd1 (epitope of the constant domain of d chain of T-cell receptor 1) and dTcS1 (epitope of the variable domain of d chain of T-cell receptor1) levels were lower in cancer patients. A clear circadian rhythm was validated for the time-qualified changes in CD4, CD20, HLA-DR with acrophase at night, and CD8, CD8 bright, CD8 dim, CD16, TcRd1 and dTcS1 with acrophase in the morning in the control group. A clear circadian rhythm was validated for the time-qualified changes in CD4 with acrophase at night, in the group of cancer patients. Results obtained in our study show that lung cancer is associated with anomalies of proportion and circadian variations of lymphocyte subsets that must be considered when adoptive immunotherapy has to be planned.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12797908     DOI: 10.1177/039463200301600211

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  7 in total

Review 1.  Perfect timing: circadian rhythms, sleep, and immunity - an NIH workshop summary.

Authors:  Jeffrey A Haspel; Ron Anafi; Marishka K Brown; Nicolas Cermakian; Christopher Depner; Paula Desplats; Andrew E Gelman; Monika Haack; Sanja Jelic; Brian S Kim; Aaron D Laposky; Yvonne C Lee; Emmanuel Mongodin; Aric A Prather; Brian J Prendergast; Colin Reardon; Albert C Shaw; Shaon Sengupta; Éva Szentirmai; Mahesh Thakkar; Wendy E Walker; Laura A Solt
Journal:  JCI Insight       Date:  2020-01-16

2.  Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls.

Authors:  Gianluigi Mazzoccoli; Robert B Sothern; Paola Parrella; Lucia A Muscarella; Vito Michele Fazio; Francesco Giuliani; Victoria Polyakova; Igor M Kvetnoy
Journal:  Clin Exp Med       Date:  2011-09-11       Impact factor: 3.984

3.  Altered time structure of neuro-endocrine-immune system function in lung cancer patients.

Authors:  Gianluigi Mazzoccoli; Gianluigi Vendemiale; Angelo De Cata; Stefano Carughi; Roberto Tarquini
Journal:  BMC Cancer       Date:  2010-06-21       Impact factor: 4.430

4.  Differentiated regulation of immune-response related genes between LUAD and LUSC subtypes of lung cancers.

Authors:  Mengzhu Chen; Xiuying Liu; Jie Du; Xiu-Jie Wang; Lixin Xia
Journal:  Oncotarget       Date:  2017-01-03

Review 5.  Circadian clock: a regulator of the immunity in cancer.

Authors:  Zhen Zhang; Puhua Zeng; Wenhui Gao; Qing Zhou; Ting Feng; Xuefei Tian
Journal:  Cell Commun Signal       Date:  2021-03-22       Impact factor: 5.712

6.  Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer.

Authors:  Abdoulaye Karaboué; Thierry Collon; Ida Pavese; Viviane Bodiguel; Joel Cucherousset; Elda Zakine; Pasquale F Innominato; Mohamed Bouchahda; René Adam; Francis Lévi
Journal:  Cancers (Basel)       Date:  2022-02-11       Impact factor: 6.639

7.  Gene Expression Profile of the A549 Human Non-Small Cell Lung Carcinoma Cell Line following Treatment with the Seeds of Descurainia sophia, a Potential Anticancer Drug.

Authors:  Bu-Yeo Kim; Jun Lee; Sung Joon Park; Ok-Sun Bang; No Soo Kim
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-27       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.